Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      *Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
      UK-VNCCLL-220184 | May 2022

      UK-VNCCLL-230011. Date of Preparation: January 2023.

      Downloadable VENCLYXTO resources

      Video library

      Haematology experts provide their opinions on key areas in the treatment of CLL patients

       

      The Breakfast CLLub: expert perspectives in CLL management

      Holistic management in CLL

      Dr Samir Agrawal, Senior Lecturer at the Queen Mary University of London and Honorary Consultant at Barts Health NHS Trust, advocates patient-empowering, holistic treatment in CLL patients.

      Infection prophylaxis in CLL

      Jess Pealing, Lead Haematology Specialist Pharmacist at The Christie Hospital Manchester, discusses prophylactic steps recommended for CLL patients to help prevent the development of infectious complications.

      (35 mins)

      (14 mins)

      CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

      References

      1. VENCLYXTO Summary of Product Characteristics.
      2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
      3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.

       

      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCCLL-220517. Date of preparation: January 2023.